Q-omics provides the consensus-scored RPL30P12 profile across patient tissues and cancer cell-line models. RPL30P12 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL30P12 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, RPL30P12 RNA expression shows 5,588 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, LUAD, and STAD as cancer lineages where RPL30P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL30P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL30P12 survival associations across molecular data types. RPL30P12 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL30P12 RNA expression–survival associations across cancer types. High RPL30P12 expression shows unfavorable associations in LIHC, STAD, BLCA and UCEC, but favorable associations in CESC and GBM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL30P12 RNA expression.
This table summarizes RPL30P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL30P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL30P12 shows higher tumor expression in LUAD and PRAD. The LUAD box plot shows higher RPL30P12 RNA expression in tumor versus normal tissue (log2 FC = +0.339, t-test p = .007).
This table shows molecular features associated with RPL30P12 in patient tissues and cancer cell lines. In patient samples, RPL30P12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
